TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35282441

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg) three times a day plus phentermine hydrochloride (37.5 mg) once daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo three times a day plus phentermine hydrochloride (37.5 mg) once daily
Number of subjects: 51
Study: 35432817

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve block anesthesia
Number of subjects: 128

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 128
Study: 33287300

Group type: EXPERIMENTAL
Intervention: Donkey milk fortifier
Number of subjects: 122

Group type: COMPARATOR
Intervention: Bovine-derived fortifier
Number of subjects: 122
Study: 36213959

Group type: EXPERIMENTAL
Intervention: Home-based care with community and primary healthcare workers' support
Number of subjects: 240

Group type: COMPARATOR
Intervention: Routine clinic-based care
Number of subjects: 240
Study: 34751777

Group type: EXPERIMENTAL
Intervention: LIPCAR levels
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: High LIPCAR levels
Number of subjects: 967
Study: 36375977

Group type: EXPERIMENTAL
Intervention: pemafibrate (0.4 mg orally per day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: omega-3 fatty acid ethyl esters (4 g orally per day)
Number of subjects: 128
Study: 32639244

Group type: EXPERIMENTAL
Intervention: Vegan diet for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: AHA-recommended diet for 8 weeks
Number of subjects: 100
Study: 35490744

Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg daily for 28 days, then 20 mg BID for 56 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34494076

Group type: EXPERIMENTAL
Intervention: Fall prevention education program (1-day face-to-face workshop)
Number of subjects: 200
Study: 33346856

Group type: EXPERIMENTAL
Intervention: Patient concerns inventory (PCI) intervention used in outpatient clinics for one year after treatment.
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (not using PCI).
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Patient concerns inventory (PCI) intervention.
Number of subjects: 288
Study: 33066800

Group type: EXPERIMENTAL
Intervention: Advanced Retrieval Practitioners (non-physicians) using ultrasound to diagnose pneumothorax
Number of subjects: 12

Group type: COMPARATOR
Intervention: Expert review of ultrasound images
Number of subjects: 12
Study: 34495879

Group type: COMPARATOR
Intervention: Low-income children
Number of subjects: 958

Group type: COMPARATOR
Intervention: Low-income children (< 2 years old)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Older children
Number of subjects: 958
Study: 32307012

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg NaHCO3 solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water as a placebo
Number of subjects: 10
Study: 33884909

Group type: EXPERIMENTAL
Intervention: Meldonium trials (details on dosage and duration not available)
Number of subjects: 0
Study: 32548759

Group type: EXPERIMENTAL
Intervention: 23 Y-STR loci analysis
Number of subjects: 310
Study: 34042297

Group type: EXPERIMENTAL
Intervention: Active commuting by bike (BIKE, n=14)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of moderate intensity (MOD, n=28)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of vigorous intensity (VIG, n=18)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CON, n=12)
Number of subjects: 72
Study: 33085578

Group type: EXPERIMENTAL
Intervention: Smoking cessation e‐visit
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study: 36531558

Group type: EXPERIMENTAL
Intervention: Isoflavone 50 mg daily for three months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo daily for three months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isoflavone 50 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33082191

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 5 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 10 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 15 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35914543

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 636

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 636
Study: 32208889

Group type: EXPERIMENTAL
Intervention: Periarticular multidrug infiltration (PMDI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Epidural catheter
Number of subjects: 58
Study: 34453416

Group type: EXPERIMENTAL
Intervention: Generic tadalafil tablet (10 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Marketed tadalafil tablet (10 mg)
Number of subjects: 53
Study: 33785656

Group type: EXPERIMENTAL
Intervention: Accentuated eccentric loading (AEL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional loading (TL)
Number of subjects: 0
Study: 32883351

Group type: EXPERIMENTAL
Intervention: Ultraviolet-cabinets (UVc) for fluorescent-alcohol-based handrubs (AHR)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (visual supervision of a tutor)
Number of subjects: 242
Study: 34516308

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 13885
Study: 32979645

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab (bev)
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Doublets (FOLFOX or FOLFIRI)/bevacizumab (bev)
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Locoregional treatments (LRTs)
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Locoregional treatments (LRTs) after first progression
Number of subjects: 1187
Study: 34579131

Group type: EXPERIMENTAL
Intervention: Sodium Selenite Injection (SE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (CTRL)
Number of subjects: 29
Study: 32059011

Group type: EXPERIMENTAL
Intervention: Improved Water, Sanitation, and Hygiene (WASH)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Improved Infant and Young Child Feeding (IYCF)
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1169
Study: 35351178

Group type: EXPERIMENTAL
Intervention: Early neurosurgical hematoma evacuation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Initial conservative management with the possibility of delayed secondary surgery
Number of subjects: 300
Study: 32252544

Group type: EXPERIMENTAL
Intervention: Individual Cognitive Stimulation Therapy (iCST), 14 sessions of 45 minutes each
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 33
Study: 36152268

Group type: EXPERIMENTAL
Intervention: anti-HBc level < 325 IU/ml
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: anti-HBc level ≥ 325 IU/ml
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc < 325 IU/ml with HBsAg >3008 IU/mL
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc < 325 IU/ml with HBcrAg ≥1790 U/ml
Number of subjects: 136
Study: 34256459

Group type: EXPERIMENTAL
Intervention: Surgical treatment for pancreatic cancer with liver metastasis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic chemotherapy (current standard treatment)
Number of subjects: 0
Study: 33586958

Group type: EXPERIMENTAL
Intervention: Discontinuous molecular dynamics (DMD) simulations of ovispirin-1 peptide on graphene surface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMD simulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrophobic graphene surface
Number of subjects: 0
Study: 32702706

Group type: EXPERIMENTAL
Intervention: Exercise plus energy restriction (EXER)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Energy restriction only (ER)
Number of subjects: 60
Study: 34137177

Group type: EXPERIMENTAL
Intervention: Autologous serum (AS) eye drops
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Allogeneic Serum (HS) eye drops
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Umbilical Cord serum (CS) eye drops
Number of subjects: 63

Group type: COMPARATOR
Intervention: Visual acuity
Number of subjects: 63

Group type: COMPARATOR
Intervention: Schirmer test
Number of subjects: 63

Group type: COMPARATOR
Intervention: Breakup time (BUT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fluorescein staining measurements
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lissamine green staining measurements
Number of subjects: 63

Group type: COMPARATOR
Intervention: Questionnaire scores
Number of subjects: 63
Study: 33274479

Group type: EXPERIMENTAL
Intervention: CsA plus steroids
Number of subjects: 209

Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 209
Study: 32731786

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 50
Study: 32116827

Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 80
Study: 36566174

Group type: EXPERIMENTAL
Intervention: vilobelimab plus best supportive care (BSC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: BSC only
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: vilobelimab plus BSC
Number of subjects: 17
Study: 34629379

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium hydrate 0.1% (NSAID group) applied twice a day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium hydrate 0.1% (NSAID group)
Number of subjects: 125
Study: 32189108

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eculizumab (during open-label extension)
Number of subjects: 0
Study: 35070287

Group type: EXPERIMENTAL
Intervention: Protein supplements (20 g of protein daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (zero protein supplements)
Number of subjects: 48
Study: 33706847

Group type: EXPERIMENTAL
Intervention: Transdiagnostic seminars combined with high-intensity CBT (TDS+CBT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: High-intensity cognitive behavioural therapy (CBT) only
Number of subjects: 106
Study: 35150804

Group type: EXPERIMENTAL
Intervention: Alcohol-based handrub (ABHR)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Handscrubbing with PVP-I
Number of subjects: 33

Group type: COMPARATOR
Intervention: Handscrubbing with CHX
Number of subjects: 33
Study: 34071718

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri OLL2716 (LG21 strain) yogurt for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo yogurt (LG21 strain-free) for 12 weeks
Number of subjects: 28
Study: 34052386

Group type: EXPERIMENTAL
Intervention: Perioperative oral pregabalin (Lyrica, twice daily starting the evening before surgery, for a total of 4 doses)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Single‐shot interscalene brachial plexus block (ISBPB, 20 ml of bupivacaine 0.25%)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Perioperative oral pregabalin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Single‐shot interscalene brachial plexus block (ISBPB)
Number of subjects: 59
Study: 32811236

Group type: EXPERIMENTAL
Intervention: 6 cycles of neoadjuvant chemotherapy (NACT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3 cycles of neoadjuvant chemotherapy (NACT)
Number of subjects: 30
Study: 34994480

Group type: EXPERIMENTAL
Intervention: Florfenicol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 130
Study: 32930131

Group type: EXPERIMENTAL
Intervention: Continuous hyper-fractionated accelerated radiotherapy week-end less (CHARTWEL) - 58.5 Gy/39 fractions/2.5 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional concurrent chemo-radiotherapy (CCRT) - 66 Gy/33 fractions/6.5 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CHARTWEL
Number of subjects: 60

Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 60
Study: 35938258

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100/25 mg three times per day for 80 weeks (early-start)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo for 40 weeks followed by levodopa/carbidopa 100/25 mg three times per day for 40 weeks (delayed-start)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Early-start treatment
Number of subjects: 445

Group type: COMPARATOR
Intervention: Delayed-start treatment
Number of subjects: 445
Study: 33992441

Group type: EXPERIMENTAL
Intervention: Concomitant administration of CYD‐TDV and bivalent HPV vaccine
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Sequential administration of CYD‐TDV and bivalent HPV vaccine
Number of subjects: 478
Study: 32594370

Group type: EXPERIMENTAL
Intervention: Low-dose RTX (Protocol 1, one dose of RTX 375 mg/m2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standard RTX protocol (Protocol 2, four weekly doses of rituximab 375 mg/m2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ponticelli’s regimen (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 42
Study: 34936819

Group type: EXPERIMENTAL
Intervention: Patient messages from cases (patients who died by suicide, were hospitalized, or presented to the ED)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Patient messages from cases
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (randomly selected group)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 33621109

Group type: EXPERIMENTAL
Intervention: Lenalidomide oral 15 mg/d, days 1‐14/21 plus standard R‐CHOP21
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo/R‐CHOP21
Number of subjects: 570
Study: 33341114

Group type: EXPERIMENTAL
Intervention: Intervention components (educational components of the multifaceted implementation program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paper-based components of the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital components of the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-time outreach visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational components for patients
Number of subjects: 0
Study: 32192317

Group type: EXPERIMENTAL
Intervention: SmartVest
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RespIn 11
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pharmacological therapy alone
Number of subjects: 60
Study: 34706682

Group type: EXPERIMENTAL
Intervention: Self-care counseling
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 35346499

Group type: EXPERIMENTAL
Intervention: Aspirin-Cinnamon
Number of subjects: 122

Group type: COMPARATOR
Intervention: Aspirin-Placebo
Number of subjects: 122
Study: 616689230

Group type: EXPERIMENTAL
Intervention: Flap anchoring with suction drains (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Suction drains alone (Group B)
Number of subjects: 200
Study: 33079009

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 236
Study: 32532267

Group type: EXPERIMENTAL
Intervention: nano-carbonate apatite dentifrice
Number of subjects: 48

Group type: COMPARATOR
Intervention: control dentifrice
Number of subjects: 48
Study: 33651438

Group type: EXPERIMENTAL
Intervention: GLP‐1RA exenatide once‐weekly (ExQW) for 36 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 36 weeks
Number of subjects: 42
Study: 34148388

Group type: EXPERIMENTAL
Intervention: Scale ultrasound
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional ultrasound
Number of subjects: 76
Study: 33436031

Group type: EXPERIMENTAL
Intervention: Recruitment strategies involving research nurse involvement and engagement of clinical colleagues.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Qualitative research techniques to explore recruitment issues.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clear presentation of medical and surgical treatment options.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pre-trial training for recruiters.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patient-clinician relationships.
Number of subjects: 19
Study: 34756787

Group type: EXPERIMENTAL
Intervention: Roxadustat treatment for 12 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Post-12 weeks follow-up
Number of subjects: 55
Study: 33771368

Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP block (LAP-arm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound-guided TAP block (US-arm)
Number of subjects: 50
Study: 36246128

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks, 40–60 min, 3 days a week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Detraining for 30 days after HIIT
Number of subjects: 23
Study: 33158422

Group type: EXPERIMENTAL
Intervention: EfiKroniK group (physical exercise programme tailored to each patient)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard healthy life prescription (PVS)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: EfiKroniK group
Number of subjects: 370
Study: 34293955

Group type: EXPERIMENTAL
Intervention: Active phase with smart insulin pen cap (alarms/reminders)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control phase (masked phase without feedback)
Number of subjects: 80
Study: 33647225

Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33378425

Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser followed by CPP‐ACP
Number of subjects: 80

Group type: COMPARATOR
Intervention: CPP‐ACP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group, no preventive measures
Number of subjects: 80
Study: 35236652

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy (Control)
Number of subjects: 100
Study: 32737670

Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment targeting emotion regulation problems over 16 weeks
Number of subjects: 37
Study: 32847924

Group type: EXPERIMENTAL
Intervention: HPV vaccination story
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: e‐cigarette story
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: General heuristics
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Presence of statistics and links to scientific research
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Feelings about news media
Number of subjects: 64
Study: 33742222

Group type: EXPERIMENTAL
Intervention: Hamstring tendon reconstruction
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Quadriceps tendon reconstruction
Number of subjects: 51
Study: 33523233

Group type: EXPERIMENTAL
Intervention: Atezolizumab and nab-Paclitaxel (A+nP)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Placebo and nab-Paclitaxel (P+nP)
Number of subjects: 902
Study: 32394851

Group type: EXPERIMENTAL
Intervention: Perindopril, indapamide SR, and metformin (n=40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Perindopril, moxonidin, and metformin (n=40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Perindopril, indapamide SR, and amlodipine (n=40)
Number of subjects: 120
Study: 34020072

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (CAZ-AVI)
Number of subjects: 90
Study: 32204134

Group type: EXPERIMENTAL
Intervention: Coaching intervention (face-to-face combined with telephone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36375331

Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 126
Study: 33186620

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 258
Study: 35343796

Group type: EXPERIMENTAL
Intervention: Probiotic group (Bifidobacterium lactis Probio-M8, atorvastatin, metoprolol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group (placebo, atorvastatin, metoprolol)
Number of subjects: 60
Study: 34670321

Group type: EXPERIMENTAL
Intervention: Isolated fetal tachycardia (FHR ≥160 bpm for at least 10 minutes)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Fetal tachycardia
Number of subjects: 728
Study: 35228291

Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation (rivaroxaban 10 mg once a day for 3 months)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Therapeutic anticoagulation (rivaroxaban 20 mg once a day for 3 months)
Number of subjects: 4
Study: 36457273

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 73
Study: 33839979

Group type: EXPERIMENTAL
Intervention: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX
Number of subjects: 0
Study: 33792511

Group type: EXPERIMENTAL
Intervention: Group psychodrama (8 sessions during hospitalization)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (waiting for treatment)
Number of subjects: 16
Study: 34719399

Group type: EXPERIMENTAL
Intervention: Magnesium oxide monohydrate (MOMH) 226 mg, once daily at bedtime for 60 days
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo, once daily at bedtime for 60 days
Number of subjects: 216
Study: 32992991

Group type: EXPERIMENTAL
Intervention: MmPylRS variants dedicated to tryptophan and tyrosine analogs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MmPylRS variants with systematic mutagenesis
Number of subjects: 0
Study: 33353864

Group type: EXPERIMENTAL
Intervention: Personal Patient Profile‐Prostate (P3P)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392